Korean Stem Cell Ventures Pursuing Divergent R&D Strategies

Two South Korean stem cell therapy ventures, Corestem and CHA Biotech, are taking divergent strategies in R&D and commercialization, one pushing ahead with the rapid launch of its first product and the other taking time to optimize its pipeline. During a recent stem cell industry investor relations session in Seoul, the companies unveiled the thinking behind their pipeline progress and business strategies.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia